A Phase 3 interventional study of Everolimus and tacrolimus and mycophenolate mofetil and tacrolimus in Kidney Transplant, sponsored by Novartis Pharmaceuticals. Completed at 50 sites in 2 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2015-11-11.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this phase 3b study is to compare the safety and efficacy of everolimus with low dose tacrolimus to mycophenolate mofetil with standard dose tacrolimus in kidney transplant recipients.
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Other protocol related inclusion/exclusion criteria may apply.
Everolimus (EVR) and tacrolimus treatment arm: Therapeutic drug monitoring of everolimus and tacrolimus was mandatory throughout the study. From Day 5 onwards, the everolimus 0.75 mg b.i.d. dose was increased if the trough level was \< 3 ng/mL, or reduced if the trough level was \> 8 ng/mL. Tacrolimus was initiated according to local practice. In this treatment arm, the tacrolimus dose was adjusted from Day 3 onwards, to a target whole blood trough concentration of 4 ng/mL to 7 ng/mL. From Month 2 until Month 6, the target tacrolimus trough level was 3 ng/mL to 6 ng/mL. After Month 6, the tacrolimus dose was adjusted in order to achieve a target trough level of 2 ng/mL to 5 ng/mL.
Drug: Everolimus and tacrolimus
Mycophenolate mofetil and tacrolimus (MMF) treatment arm: MMF dose was initiated at 1 g b.i.d. (2 g/day). Adjustments were to be made for adverse events including, but not limited to, gastrointestinal intolerance and decrease in WBC. MMF trough or AUC was not used to adjust dosing. In this group, tacrolimus was initiated according to local practice. Tacrolimus dose was adjusted from Day 3 on to achieve a target whole blood trough concentration of 8 ng/mL to 12 ng/mL. From Month 2 until Month 6, target tacrolimus trough level was reduced to 7 - 10 ng/mL. After Month 6, target level of tacrolimus was reduced to 5 - 8 ng/mL.
Drug: mycophenolate mofetil and tacrolimus
Drug pages: Everolimus · Tacrolimus
Everolimus: * Dosage form: 0.75 mg, 0.25 mg, and 0.5 mg tablets * Dose: 1.5 mg per day * Frequency: 0.75 mg twice daily Tacrolimus: * Dose adjusted to maintain specific blood levels
Drug pages: Mycophenolic Acid · Tacrolimus
Mycophenolate mofetil: - Dose form: 250 mg capsule - Dose: 2g per day - Frequency: 1g twice daily Tacrolimus: - Dose adjusted to maintain specific blood levels
Also known as: Active Comparator Control)
Number of Participants With Incidence of Composite Efficacy Failure
Efficacy failure rate used the composite endpoint of: (1) treated biopsy-proven acute rejection (BPAR)\*, (2) graft loss\*\*, (3) participant death or(4) loss to follow-up. \*A treated BPAR was defined as a biopsy graded IA, IB, IIA, IIB, or III and which was treated with anti-rejection therapy. \*\*Graft loss is defined as when the allograft was presumed lost on the day the participant started dialysis and was not able to subsequently be removed from dialysis.
Time frame: 12 Months
Estimated Glomerular Filtration Rate (eGFR)
Renal function was assessed by estimated Glomerular Filtration Rate (eGFR) using the Modification of Diet in Renal Disease (MDRD) formula. MDRD formula: GFR \[mL/min/1.73m˄2\] = 186.3\*(C˄-1.154)\*(A˄-0.203)\*G\*R. DEFINITIONS: C = serum concentration of creatinine \[mg/dL\]; A = age \[years\]; G = 0.742 when gender is female, otherwise G = 1; R = 1.21 when race is black, otherwise R = 1
Time frame: 12 Months
Number of Participants With Incidence of CMV (Viremia, Syndrome and Disease)
Participants with incidence of CMV (viremia, syndrome and disease). CMV is cytomegalovirus.
Time frame: 12 Months
Number of Participants With Incidence Rates of BKV Viremia, BKV Viruria, or BKV Nephropathy
Participants with Incidence of BKV (viremia, viruria, or nephropathy). BKV is Polyomavirus type BK.
Time frame: 12 Months
Number of Participants With Incidence of New Onset of Diabetes Mellitus
Incidence of new onset diabetes mellitus defined as non-diabetic patients before transplantation, who are receiving glucose lowering treatment for more than 30 days post-transplant, or with a random plasma glucose ≥200 mg dL (11.1 mmol/L) with 2 fasting plasma glucose values ≥126 mg/dL (7 mmol/L)
Time frame: 12 Months
Number of Participants With Incidence of Proteinuria Events
Number of participants with Incidence of proteinuria events indicating chronic kidney disease
Time frame: Baseline and 12 Months
Number of Participants With Incidence of Adverse Events, Serious Adverse Events, and Tacrolimus-associated Adverse Events
Incidence of adverse events, serious adverse events, and tacrolimus-associated adverse events by System Organ Class
Time frame: 12 Months
In total 738 participants were screened, and 613 were transplanted and randomized to treatment (n=309 to EVR+Low TAC dose and n=304 to MMF+Std TAC). EVR=Everolimus and low dose tacrolimus, and MMF=Mycophenolate mofetil and standard dose tacrolimus.
| Milestone | Everolimus and Low Dose Tacrolimus | Mycophenolate Mofetil and Standard Dose Tacrolimus |
|---|---|---|
| Started | 309 | 304 |
| Completed | 204 | 232 |
| Not completed | 105 | 72 |
| Withdrew: Adverse event | 66 | 39 |
| Withdrew: Protocol deviation | 9 | 8 |
| Withdrew: Withdrawal by subject | 8 | 9 |
| Withdrew: Administrative problems | 7 | 5 |
| Withdrew: Unsatisfactory therapeutic effect | 7 | 0 |
| Withdrew: Abnormal test procedure | 4 | 0 |
| Withdrew: Graft loss | 2 | 5 |
| Withdrew: Death | 2 | 2 |
| Withdrew: Abnormal lab values | 0 | 2 |
| Withdrew: Subject no longer required study drug | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Milestone | Everolimus and Low Dose Tacrolimus | Mycophenolate Mofetil and Standard Dose Tacrolimus |
|---|---|---|
| Started | 309 | 304 |
| Completed | 293 | 282 |
| Not completed | 16 | 22 |
| Withdrew: Withdrawal by subject | 8 | 16 |
| Withdrew: Death | 6 | 5 |
| Withdrew: Missing | 2 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 |
Efficacy failure rate used the composite endpoint of: (1) treated biopsy-proven acute rejection (BPAR)\*, (2) graft loss\*\*, (3) participant death or(4) loss to follow-up. \*A treated BPAR was defined as a biopsy graded IA, IB, IIA, IIB, or III and which was treated with anti-rejection therapy. \*\*Graft loss is defined as when the allograft was presumed lost on the day the participant started dialysis and was not able to subsequently be removed from dialysis.
| Participants | Everolimus and Low Dose Tacrolimus | Mycophenolate Mofetil and Standard Dose Tacrolimus |
|---|---|---|
| Composite Endpoint | 76 | 62 |
| Treated Biopsy-proven Acute rejection (BPAR) | 59 | 34 |
| Graft Loss | 4 | 12 |
| Death | 6 | 5 |
| Loss to follow up | 9 | 17 |
Renal function was assessed by estimated Glomerular Filtration Rate (eGFR) using the Modification of Diet in Renal Disease (MDRD) formula. MDRD formula: GFR \[mL/min/1.73m˄2\] = 186.3\*(C˄-1.154)\*(A˄-0.203)\*G\*R. DEFINITIONS: C = serum concentration of creatinine \[mg/dL\]; A = age \[years\]; G = 0.742 when gender is female, otherwise G = 1; R = 1.21 when race is black, otherwise R = 1
| mL/min/1.73m˄2 | Everolimus and Low Dose Tacrolimus | Mycophenolate Mofetil and Standard Dose Tacrolimus |
|---|---|---|
| Estimated Glomerular Filtration Rate (eGFR) | 63.14 ± 22.042 | 63.06 ± 19.512 |
Participants with incidence of CMV (viremia, syndrome and disease). CMV is cytomegalovirus.
| Participants | Everolimus and Low Dose Tacrolimus | Mycophenolate Mofetil and Standard Dose Tacrolimus |
|---|---|---|
| CMV syndrome event | 9 | 13 |
| Lab evidence of CMV Viremia | 7 | 10 |
| CMV Disease | 2 | 8 |
Participants with Incidence of BKV (viremia, viruria, or nephropathy). BKV is Polyomavirus type BK.
| Participants | Everolimus and Low Dose Tacrolimus | Mycophenolate Mofetil and Standard Dose Tacrolimus |
|---|---|---|
| Lab evidence of BKV Viremia | 19 | 27 |
| Lab evidence of BKV Viruria | 19 | 15 |
| BKV Disease (Nephropathy) | 5 | 5 |
Incidence of new onset diabetes mellitus defined as non-diabetic patients before transplantation, who are receiving glucose lowering treatment for more than 30 days post-transplant, or with a random plasma glucose ≥200 mg dL (11.1 mmol/L) with 2 fasting plasma glucose values ≥126 mg/dL (7 mmol/L)
| Participants | Everolimus and Low Dose Tacrolimus | Mycophenolate Mofetil and Standard Dose Tacrolimus |
|---|---|---|
| Any New Onset Diabetes | 25 | 22 |
| randomGlucose≥200mg/dL w/2 fastingGlucose≥126mg/dL | 15 | 12 |
| Concomitant Diabetes medicine for 30 days or more | 13 | 14 |
Number of participants with Incidence of proteinuria events indicating chronic kidney disease
| Participants | Everolimus and Low Dose Tacrolimus | Mycophenolate Mofetil and Standard Dose Tacrolimus |
|---|---|---|
| Baseline: Proteinuria (>=300 mg/g) | 243 | 250 |
| Month 12, Day 316-450: Proteinuria (>=300 mg/g) | 36 | 35 |
Incidence of adverse events, serious adverse events, and tacrolimus-associated adverse events by System Organ Class
| Participants | Everolimus and Low Dose Tacrolimus | Mycophenolate Mofetil and Standard Dose Tacrolimus |
|---|---|---|
| Any system organ class | 303 | 302 |
| Metabolism and nutrition disorders | 266 | 263 |
| Gastrointestinal disorders | 233 | 247 |
| Injury, poisoning and procedural complications | 223 | 202 |
| General disorders &administration site conditions | 199 | 177 |
| Infections and infestations | 184 | 196 |
| Investigations | 150 | 143 |
| Renal and urinary disorders | 141 | 160 |
| Vascular disorders | 131 | 121 |
| Blood and lymphatic system disorders | 130 | 163 |
| Nervous system disorders | 125 | 150 |
| Respiratory, thoracic and mediastinal disorders | 122 | 134 |
| Musculoskeletal and connective tissue disorders | 110 | 114 |
| Skin and subcutaneous tissue disorders | 109 | 108 |
| Psychiatric disorders | 96 | 106 |
| Reproductive system and breast disorders | 56 | 40 |
| Cardiac disorders | 51 | 47 |
| Eye disorders | 26 | 36 |
| Immune system disorders | 13 | 11 |
| Endocrine disorders | 12 | 8 |
| Neoplasms benign,malignant,other incl cysts/polyps | 10 | 15 |
| Ear and labyrinth disorders | 7 | 11 |
| Hepatobiliary disorders | 6 | 3 |
| Surgical and medical procedures | 2 | 0 |
| Congenital, familial and genetic disorders | 0 | 6 |
| Social circumstances | 0 | 1 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Everolimus and Low Dose Tacrolimus | — | 154/306 (50.3%) | 302/306 (98.7%) |
| Mycophenolate Mofetil and Standard Dose Tacrolimus | — | 142/304 (46.7%) | 299/304 (98.4%) |
| Event | Everolimus and Low Dose Tacrolimus | Mycophenolate Mofetil and Standard Dose Tacrolimus |
|---|---|---|
| Urinary tract infectionInfections and infestations | 22/306 | 24/304 |
| Renal failure acuteRenal and urinary disorders | 7/306 | 16/304 |
| Blood creatinine increasedInvestigations | 10/306 | 14/304 |
| PyrexiaGeneral disorders | 13/306 | 11/304 |
| PneumoniaInfections and infestations | 13/306 | 7/304 |
| Graft dysfunctionInjury, poisoning and procedural complications | 9/306 | 8/304 |
| DiarrhoeaGastrointestinal disorders | 7/306 | 8/304 |
| VomitingGastrointestinal disorders | 8/306 | 7/304 |
| UrosepsisInfections and infestations | 5/306 | 7/304 |
| Diabetes mellitusMetabolism and nutrition disorders | 2/306 | 7/304 |
| Event | Everolimus and Low Dose Tacrolimus | Mycophenolate Mofetil and Standard Dose Tacrolimus |
|---|---|---|
| NauseaGastrointestinal disorders | 111/306 | 134/304 |
| HypomagnesaemiaMetabolism and nutrition disorders | 102/306 | 124/304 |
| DiarrhoeaGastrointestinal disorders | 74/306 | 122/304 |
| ConstipationGastrointestinal disorders | 119/306 | 120/304 |
| Oedema peripheralGeneral disorders | 113/306 | 88/304 |
| HypophosphataemiaMetabolism and nutrition disorders | 108/306 | 94/304 |
| Procedural painInjury, poisoning and procedural complications | 93/306 | 94/304 |
| HyperkalaemiaMetabolism and nutrition disorders | 93/306 | 81/304 |
| TremorNervous system disorders | 51/306 | 86/304 |
| AnaemiaBlood and lymphatic system disorders | 83/306 | 67/304 |
Full Analysis Set (FAS) consisted of all participants randomized after transplantation. \*The discrepancy with the Ns is that there are 613 participants overall and 610 in the safety population.
| Age, Continuous(Years) | Everolimus and Low Dose Tacrolimus | Mycophenolate Mofetil and Standard Dose Tacrolimus | Total |
|---|---|---|---|
| Mean | 50.00 ± 13.34 | 48.4 ± 12.91 | 49.2 ± 13.14 |
| Sex: Female, Male(Participants) | Everolimus and Low Dose Tacrolimus | Mycophenolate Mofetil and Standard Dose Tacrolimus | Total |
|---|---|---|---|
| Female | 101 | 102 | 203 |
| Male | 205 | 202 | 407 |
| Race/Ethnicity, Customized(Participants) | Everolimus and Low Dose Tacrolimus | Mycophenolate Mofetil and Standard Dose Tacrolimus | Total |
|---|---|---|---|
| American Indian or Alaska Native | 3 | 1 | 4 |
| Asian | 17 | 11 | 28 |
| Native Hawaiian or Other Pacific Islander | 3 | 1 | 4 |
| Black or African American | 70 | 74 | 144 |
| Caucasian | 196 | 201 | 397 |
| Other | 17 | 16 | 33 |
| BMI(kg/m˄2) | Everolimus and Low Dose Tacrolimus | Mycophenolate Mofetil and Standard Dose Tacrolimus | Total |
|---|---|---|---|
| Mean | 27.7 ± 5.55 | 28.3 ± 5.13 | 28.0 ± 5.35 |
| Diabetic status at randomization(Participants) | Everolimus and Low Dose Tacrolimus | Mycophenolate Mofetil and Standard Dose Tacrolimus | Total |
|---|---|---|---|
| Yes | 111 | 95 | 206 |
| No | 195 | 209 | 404 |
The record gives a start of Jan 2010, a primary completion of Mar 2013 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2014, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Everolimus · Tacrolimus